quinazolines has been researched along with entinostat in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bunn, PA; Hirsch, FR; Jotte, RM; Konduri, K; Neubauer, MA; Ruxer, RL; Spira, AI; Varella-Garcia, M; Witta, SE | 1 |
Chen, M; Hu, L; Yang, X; Zhang, Q | 1 |
Bartholomeusz, C; Hortobagyi, GN; Humphries, J; Lee, J; Mansour, O; Ordentlich, P; Ueno, NT | 1 |
1 trial(s) available for quinazolines and entinostat
Article | Year |
---|---|
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines; Quinazolines | 2012 |
2 other study(ies) available for quinazolines and entinostat
Article | Year |
---|---|
Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Drug Interactions; Lapatinib; Male; Mass Spectrometry; Pyridines; Quinazolines; Rats; Rats, Sprague-Dawley | 2014 |
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |